Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 30;36(4):doad006.
doi: 10.1093/dote/doad006.

Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer

Affiliations

Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer

Satoru Matsuda et al. Dis Esophagus. .

Abstract

Abundant lymphatic flow and the anatomical location of the esophagus can result in the widespread distribution of lymph node metastasis of esophageal cancer from the cervical to the abdominal field. Historically, the Japan Esophageal Society and American Joint Committee on Cancer offer two different classifications of lymph node group location surrounding the esophagus. The location of sentinel lymph nodes in midthoracic esophageal cancer reflects the variety of lymphatic drainage routes. In fact, in cT1N0 esophageal cancer, pathological lymph node metastasis has been observed from the cervical to the abdominal field, and the locations were shown to be closely linked to the primary tumor location in advanced stages. While the impact of histology on the distribution of LN metastasis has been extensively debated, a recent prospective study on esophagogastric junction cancer found that metastatic patterns did not differ by histology. Thoracic duct lymph nodes were defined as one of the regional lymph node stations in the mediastinum. Although lymph node metastasis around the thoracic duct has occasionally been observed, the oncologic impact of thoracic duct lymph node dissection has not been fully elucidated. To eradicate tumors locoregionally, three-field lymph node dissection, a strategy for extended lymph node clearance, has been established. In esophagectomy, three-field lymph node dissection is defined as a procedure for complete regional cervico-thoraco-abdominal lymph node dissection. However, its therapeutic efficacy must be evaluated based on the balance between oncological outcomes and possible added surgical risk. To further improve survival, multidisciplinary treatment consisting of surgery, chemotherapy, and radiotherapy has been established worldwide as a standard treatment for esophageal cancer. Now that neoadjuvant therapy followed by esophagectomy is the standard, adding adjuvant therapy including immunotherapy could be a promising treatment option. The ideal combination of various multidisciplinary treatment approaches and extensive LN dissection need to be established to improve the oncological outcomes for EC patients.

Keywords: esophageal cancer; lymph node metastasis; multidisciplinary treatment; three-field lymph adenectomy.

PubMed Disclaimer

Conflict of interest statement

Dr Kitagawa has received grants and personal fees from ASAHI KASEI PHARMA CORPORATION, grants, personal fees and other from ONO PHARMACEUTICAL CO., LTD., grants and personal fees from Otsuka Pharmaceutical Factory, Inc., grants and personal fees from Nippon Covidien Inc., grants, personal fees and other from TAIHO PHARMACEUTICAL CO., LTD, grants, personal fees and other from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from KAKEN PHARMACEUTICAL CO., LTD., personal fees from AstraZeneca K.K., personal fees from Ethicon Inc., personal fees from Olympus Corporation, personal fees from SHIONOGI & CO., LTD., personal fees and other from Bristol-Myers Squibb K.K., personal fees from MSD K.K., personal fees from Smith & Nephew KK, personal fees from ASKA Pharmaceutical Co., Ltd., personal fees from MIYARISAN PHARMACEUTICAL CO. LTD., personal fees from Toray Industries, Inc., personal fees from DAIICHI SANKYO COMPANY, LIMITED, personal fees from Chugai Foundation for Innovative Drug Discovery Science, personal fees from Nippon Kayaku Co., Ltd., grants from Yakult Honsha Co. Ltd., grants from Otsuka Pharmaceutical Co., Ltd., grants from TSUMURA & CO., grants from Sumitomo Pharma Co., Ltd., grants and personal fees from EA Pharma Co., Ltd., grants from Eisai Co., Ltd., grants from Kyowa Kirin Co., Ltd., grants from MEDICON INC., grants from Takeda Pharmaceutical Co., Ltd., grants from TEIJIN PHARMA LIMITED., personal fees from Intuitive Surgical G.K., outside the submitted work.

Figures

Fig. 1
Fig. 1
Distribution of sentinel LNs of cT1b/2N0 EC located at the midthoracic esophagus. (EC, esophageal cancer; LN, lymph node.)
Fig. 2
Fig. 2
Distribution of metastatic LNs in cT1bN0 EC located at the midthoracic esophagus. (EC, esophageal cancer; LN, lymph node.)
Fig. 3
Fig. 3
Distribution of metastatic LNs in pT1N+ AC of the EGC. (AC, adenocarcinoma; EGC, esophagogastric junction; LN, lymph node.)
Fig. 4
Fig. 4
Surgical strategy based on the location of the primary tumor.

References

    1. Sung H, Ferlay J, Siegel R L et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 2021; 71: 209–49. - PubMed
    1. Watanabe M, Toh Y, Ishihara R et al. Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus 2022; 19: 1–26. - PMC - PubMed
    1. Japan Esophageal S . Japanese classification of Esophageal cancer, 11th edition: part II and III. Esophagus 2017; 14: 37–65. - PMC - PubMed
    1. Japan Esophageal S . Japanese classification of Esophageal cancer, 11th edition: part I. Esophagus 2017; 14: 1–36. - PMC - PubMed
    1. Rice T W, Patil D T, Blackstone E H. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg 2017; 6: 119–30. - PMC - PubMed